DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24
Filed with ASX · · 4 pages · English
In the deck
Story so far
Earlier from Dimerix
- Approval received for Paediatric Investigation Plan from EMA
- Dimerix confirms Phase 3 study design appropriate for China
- Prospectus
- Dimerix Announces Update on Successful Capital Raise
- Rights Issue Prospectus
Later from Dimerix
- Successful Completion of 2nd DSMB Review of FSGS Trial
- Dimerix Receives $8.9M R&D Tax Incentive Rebate
- Regulatory Approval received in Malaysia for ACTION3 Study
- FDA Approves Qytovra Brand Name
- Dimerix Announces License Agreement for EU, Canada, ANZ
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix